Nuclear Medicine and Biology
Volume 37, Issue 5 , Pages 577-586 , July 2010

FlipADAM: a potential new SPECT imaging agent for the serotonin transporter

  • Julie L. Wang

      Affiliations

    • Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    • ,
  • Eric C. Deutsch

      Affiliations

    • Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    • ,
  • Shunichi Oya

      Affiliations

    • Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    • ,
  • Hank F. Kung

      Affiliations

    • Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    • Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    • Corresponding Author InformationCorresponding author. Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. Tel.: +1 215 662 3096; fax: +1 215 349 5035.

Received 8 December 2009 ,Revised 9 February 2010 ,Accepted 27 February 2010.

References 

  1. Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry. 2004;4:5–10
  2. Nemeroff CB. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res. 2006;
  3. Zhou Z, Zhen J, Karpowich NK, Law CJ, Reith ME, Wang DN. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat Struct Mol Biol. 2009;16:652–657
  4. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [11C]DASB PET imaging study. Am J Psychiatry. 2001;158:1843–1849
  5. Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S. [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. Synapse. 2003;47:123–133
  6. Kumar JS, Prabhakaran J, Erlandsson K, Majo VJ, Simpson NR, Pratap M, et al. Synthesis and in vivo evaluation of [O-methyl-11C](2R,4R)-4-hydroxy-2-[2-[2-[2-(3-methoxy)phenyl]ethyl]phenoxy]ethyl-1-methylpyrrolidine as a 5-HT2A receptor PET ligand. Nucl Med Biol. 2006;33:565–574
  7. Chou YH, Yang BH, Chung MY, Chen SP, Su TP, Chen CC, et al. Imaging the serotonin transporter using (123)I-ADAM in the human brain. Psychiatry Res. 2009;172:38–43
  8. Koskela A, Kauppinen T, Keski-Rahkonen A, Sihvola E, Kaprio J, Rissanen A, et al. Brain serotonin transporter binding of [123I]ADAM: within-subject variation between summer and winter data. Chronobiol Int. 2008;25:657–665
  9. Koch W, Schaaff N, Popperl G, Mulert C, Juckel G, Reicherzer M, et al. [I-123] ADAM and SPECT in patients with borderline personality disorder and healthy control subjects. J. Psychiatry Neurosci. 2007;32:234–240
  10. Schuh-Hofer S, Richter M, Geworski L, Villringer A, Israel H, Wenzel R, et al. Increased serotonin transporter availability in the brainstem of migraineurs. J Neurol. 2007;254:789–796
  11. Yang YK, Yao WJ, Yeh TL, Lee IH, Chen KC, Lu RB. Association between serotonin transporter availability and hostility scores in healthy volunteers - a single photon emission computed tomography study with [(123)I] ADAM. Psychiatry Res. 2007;154:281–284
  12. Catafau AM, Perez V, Plaza P, Pascual JC, Bullich S, Suarez M, et al. Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study. Psychopharmacology (Berl). 2006;189:145–153
  13. Hinz R, Selvaraj S, Murthy NV, Bhagwagar Z, Taylor M, Cowen PJ, et al. Effects of citalopram infusion on the serotonin transporter binding of [11C]DASB in healthy controls. J Cereb Blood Flow Metab. 2008;28:1478–1490
  14. Brown AK, George DT, Fujita M, Liow JS, Ichise M, Hibbeln J, et al. PET [11C]DASB imaging of serotonin transporters in patients with alcoholism. Alcohol Clin Exp Res. 2007;31:28–32
  15. Frankle WG, Slifstein M, Gunn RN, Huang Y, Hwang DR, Darr EA, et al. Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: reproducibility and comparison of methods. J Nucl Med. 2006;47:815–826
  16. Guo Y, Chen X, Jia H, Ji X, Liu B. Synthesis and biological evaluation of one novel technetium-99m-labeled nitroquipazine derivative as an imaging agent for serotonin transporter. Appl Radiat Isot. 2008;66:1804–1809
  17. Karramkam M, Dolle F, Valette H, Besret L, Bramoulle Y, Hinnen F, et al. Synthesis of a fluorine-18-labelled derivative of 6-nitroquipazine, as a radioligand for the In vivo serotonin transporter imaging with PET. Bioorg Med Chem. 2002;10:2611–2623
  18. Kretzschmar M, Brust P, Zessin J, Cumming P, Bergmann R, Johannsen B. Autoradiographic imaging of the serotonin transporter in the brain of rats and pigs using S-([18F]fluoromethyl)-(+)-McN5652. Eur Neuropsychopharmacol. 2003;13:387–397
  19. Kakiuchi T, Tsukada H, Fukumoto D, Nishiyama S. Effects of aging on serotonin transporter availability and its response to fluvoxamine in the living brain: PET study with [(11)C](+)McN5652 and [(11)C](-)McN5652 in conscious monkeys. Synapse. 2001;40:170–179
  20. Ruhe HG, Booij J, Reitsma JB, Schene AH. Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender. Eur J Nucl Med Mol Imaging. 2009;36:841–849
  21. Stehouwer JS, Jarkas N, Zeng F, Voll RJ, Williams L, Camp VM, et al. Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3′-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. J Med Chem. 2008;51:7788–7799
  22. Joensuu M, Tolmunen T, Saarinen PI, Tiihonen J, Kuikka J, Ahola P, et al. Reduced midbrain serotonin transporter availability in drug-naive patients with depression measured by SERT-specific [(123)I] nor-beta-CIT SPECT imaging. Psychiatry Res. 2007;154:125–131
  23. Wang JL, Parhi AK, Oya S, Lieberman B, Kung HF. In vivo characterization of a series of 18F-diaryl sulfides (18F-2-(2′-((dimethylamino)methyl)-4′-(fluoroalkoxy)phenylthio)benzenamine) for PET imaging of the serotonin transporter. J Nucl Med. 2009;50:1509–1517
  24. Wang JL, Parhi AK, Oya S, Lieberman B, Kung MP, Kung HF. 2-(2′-((Dimethylamino)methyl)-4′-(3-[(18)F]fluoropropoxy)-phenylthio)benze namine for positron emission tomography imaging of serotonin transporters. Nucl Med Biol. 2008;35:447–458
  25. Parhi AK, Wang JL, Oya S, Choi SR, Kung MP, Kung HF. 2-(2′-((Dimethylamino)methyl)-4′-(fluoroalkoxy)-phenylthio)benzenamine Derivatives as Serotonin Transporter Imaging Agents. J Med Chem. 2007;50:6673–6684
  26. Mavel S, Vercouillie J, Garreau L, Raguza T, Ravna AW, Chalon S, et al. Docking study, synthesis, and in vitro evaluation of fluoro-MADAM derivatives as SERT ligands for PET imaging. Bioorg Med Chem. 2008;16:9050–9055
  27. Zhu Z, Guo N, Narendran R, Erritzoe D, Ekelund J, Hwang DR, et al. The new PET imaging agent [11C]AFE is a selective serotonin transporter ligand with fast brain uptake kinetics. Nucl Med Biol. 2004;31:983–994
  28. Huang Y, Narendran R, Bae SA, Erritzoe D, Guo N, Zhu Z, et al. A PET imaging agent with fast kinetics: synthesis and in vivo evaluation of the serotonin transporter ligand [11C]2-[2-dimethylaminomethylphenylthio)]-5-fluorophenylamine ([11C]AFA). Nucl Med Biol. 2004;31:727–738
  29. Shiue GG, Choi SR, Fang P, Hou C, Acton PD, Cardi C, et al. N,N-dimethyl-2-(2-amino-4-(18)F-fluorophenylthio)-benzylamine (4-(18)F-ADAM): an improved PET radioligand for serotonin transporters. J Nucl Med. 2003;44:1890–1897
  30. Oya S, Choi SR, Coenen H, Kung HF. New PET Imaging Agent for the Serotonin Transporter: [18F]ACF (2-[(2-Amino-4-chloro-5-fluorophenyl)thio]-N,N-dimethyl-benzenmethanamine). J Med Chem. 2002;45:4716–4723
  31. Lundberg J, Odano I, Olsson H, Halldin C, Farde L. Quantification of 11C-MADAM binding to the serotonin transporter in the human brain. J Nucl Med. 2005;46:1505–1515
  32. Jarkas N, McConathy J, Votaw JR, Voll RJ, Malveaux E, Camp VM, et al. Synthesis and characterization of EADAM: a selective radioligand for mapping the brain serotonin transporters by positron emission tomography. Nucl Med Biol. 2005;32:75–86
  33. Jarkas N, Votaw JR, Voll RJ, Williams L, Camp VM, Owens MJ, et al. Carbon-11 HOMADAM: a novel PET radiotracer for imaging serotonin transporters. Nucl Med Biol. 2005;32:211–224
  34. Kung MP, Hou C, Oya S, Mu M, Acton PD, Kung HF. Characterization of [123I]IDAM as a novel single-photon emission tomography tracer for serotonin transporters. Eur J Nucl Med. 1999;26:844–853
  35. Choi SR, Hou C, Oya S, Mu M, Kung MP, Siciliano M, et al. Selective in vitro and in vivo binding of [(125)I]ADAM to serotonin transporters in rat brain. Synapse. 2000;38:403–412
  36. Kung HF, Newman S, Choi SR, Oya S, Hou C, Zhuang ZP, et al. 2-(2-(dimethylaminomethyl)phenoxy)-5-iodophenylamine: an improved serotonin transporter imaging agent. J Med Chem. 2004;47:5258–5264
  37. Wilson AA, Ginovart N, Schmidt M, Meyer JH, Threlkeld PG, Houle S. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of 11C-labeled 2-(phenylthio)araalkylamines. J Med Chem. 2000;43:3103–3110
  38. Vercouillie J, Mavel S, Galineau L, Ragusa T, Innis R, Kassiou M, et al. Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands. Bioorg Med Chem Lett. 2006;16:1297–1300
  39. Zessin J, Deuther-Conrad W, Kretzschmar M, Wust F, Pawelke B. Brust P, et al. [11C]SMe-ADAM, an imaging agent for the brain serotonin transporter: synthesis, pharmacological characterization and microPET studies in rats. Nucl Med Biol. 2006;33:53–63
  40. Oya S, Kung MP, Acton PD, Mu M, Hou C, Kung H. A new single-photon emission computed tomography imaging agent for serotonin transporters: [123I] IDAM, 5-Iodo-2-((2-((dimethylamino)methyl)phenyl)thio)benzyl alcohol. J Med Chem. 1999;42:333–335
  41. Oya S, Choi SR, Hou C, Mu M, Kung MP, Acton PD, et al. 2-((2-((Dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nucl Med Biol. 2000;27:249–254
  42. Booij J, de Win MM. Brain kinetics of the new selective serotonin transporter tracer [(123)I]ADAM in healthy young adults. Nucl Med Biol. 2006;33:185–191
  43. Lin KJ, Liu CY, Wey SP, Hsiao IT, Wu J, Fu YK, et al. Brain SPECT imaging and whole-body biodistribution with [(123)I]ADAM — a serotonin transporter radiotracer in healthy human subjects. Nucl Med Biol. 2006;33:193–202
  44. Newberg AB, Plossl K, Mozley PD, Stubbs JB, Wintering N, Udeshi M, et al. Biodistribution and imaging with (123)I-ADAM: a serotonin transporter imaging agent. J Nucl Med. 2004;45:834–841
  45. Sacher J, Asenbaum S, Klein N, Geiss-Granadia T, Mossaheb N, Poetzi C, et al. Binding kinetics of 123 I[ADAM] in healthy controls: a selective SERT radioligand. Int J Neuropsychopharmacol. 2006;1–8
  46. Catafau AM, Perez V, Penengo MM, Bullich S, Danus M, Puigdemont D, et al. SPECT of serotonin transporters using 123I-ADAM: optimal imaging time after bolus injection and long-term test-retest in healthy volunteers. J Nucl Med. 2005;46:1301–1309
  47. Newberg AB, Amsterdam JD, Wintering N, Ploessl K, Swanson RL, Shults J, et al. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med. 2005;46:973–977
  48. Klein N, Sacher J, Geiss-Granadia T, Mossaheb N, Attarbaschi T, Lanzenberger R, et al. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology (Berl). 2007;191:333–339
  49. Koskela AK, Keski-Rahkonen A, Sihvola E, Kauppinen T, Kaprio J, Ahonen A, et al. Serotonin transporter binding of [123I]ADAM in bulimic women, their healthy twin sisters, and healthy women: a SPET study. BMC psychiatry. 2007;7:19
  50. Lundgren JD, Newberg AB, Allison KC, Wintering NA, Ploessl K, Stunkard AJ. 123I-ADAM SPECT imaging of serotonin transporter binding in patients with night eating syndrome: a preliminary report. Psychiatry Res. 2008;162:214–220
  51. Pogarell O, Koch W, Schaaff N, Popperl G, Mulert C, Juckel G, et al. [123I] ADAM brainstem binding correlates with the loudness dependence of auditory evoked potentials. Eur Arch Psychiatry Clin Neurosci. 2008;258:40–47
  52. Li IH, Huang WS, Yeh CB, Liao MH, Chen CC, Shen LH, et al. Dual-isotope single-photon emission computed tomography for dopamine and serotonin transporters in normal and Parkinsonian monkey brains. Nucl Med Biol. 2009;36:605–611
  53. Erlandsson K, Sivananthan T, Lui D, Spezzi A, Townsend CE, Mu S, et al. Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study. Eur J Nucl Med Mol Imaging. 2005;32:1329–1336
  54. Huang Y, Hwang DR, Narendran R, Sudo Y, Chatterjee R, Bae SA, et al. Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM. J Cereb Blood Flow Metab. 2002;22:1377–1398
  55. Oya S, Choi SR, Kung MP, Kung HF. 5-Chloro-2-(2′-((dimethylamino)methyl)-4′-iodophenylthio)benzenamine: a new serotonin transporter ligand. Nucl Med Biol. 2007;34:129–139
  56. Lin KJ, Yen TC, Wey SP, Hwang JJ, Ye XX, Tzen KY, et al. Characterization of the binding sites for 123I-ADAM and the relationship to the serotonin transporter in rat and mouse brains using quantitative autoradiography. J Nucl Med. 2004;45:673–681
  57. Xie T, Tong L, McLane MW, Hatzidimitriou G, Yuan J, McCann U, et al. Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology. 2006;31:2639–2651
  58. Ordway GA, Stockmeier CA, Cason GW, Klimek V. Pharmacology and distribution of norepinephrine transporters in the human locus coeruleus and raphe nuclei. J Neurosci. 1997;17:1710–1719

☆ Financial support: This work was supported by a grant awarded from the National Institutes of Health (ROI-MH068782, H.F.K.).

PII: S0969-8051(10)00035-1

doi: 10.1016/j.nucmedbio.2010.02.010

Nuclear Medicine and Biology
Volume 37, Issue 5 , Pages 577-586 , July 2010

Article Tools

* Image Usage & Resolution